Table 1 WIHS specimens’ infection duration and viral and host factors.

From: The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards

Subject	Visit	Documented Infection Duration (Days)^a	Subtype	Risk Behaviour	ART status	Viral Load (RNA copies/ml)	CD4 Count (cells/mm³)	Number of Sequences
TY2947	18	[81–251]	B	NS	Naive	920	967	14
	22	[732–902]	B	NS	Naive	6400	767	15
	24	[1105–1275]	B	NS	Naive	8500	631	12
RH7057	3	[0–146]	B	NS	Naive	14000	700	17
	4	[188–334]	B	NS	Naive	15000	252	14
	5	[384–530]	B	NS	Experienced	1592	328	13
	7	[733–879]	B	NS	Experienced	4800	374	10
	10	[1126–1272]	B	NS	Experienced	3200	359	11
IS5366	18	[1085–1945]	B	NS	Naive	1100	125	13
GE6106	9	[0–183]	B	IDU	Naive	NS	804	18
	10	[182–365]	B	IDU	Naive	230	510	10
	11	[350–533]	B	IDU	Naive	190000	576	13
	13	[728–911]	B	IDU	Naive	45000	552	17
	15	[1133–1316]	B	IDU	Naive	160000	431	13
UN2011	22	[1079–2123]	B	IDU	Experienced	3800	458	12
OY9080	17	[0–187]	B	Heterosexual	Naive	NS	NS	10
	18	[183–370]	B	Heterosexual	Naive	50000	585	11
	19	[357–544]	B	Heterosexual	Naive	45000	573	11
	21	[723–910]	B	Heterosexual	Naive	48000	319	11
	23	[1087–1274]	B	Heterosexual	Naive	34000	308	11
DA1342	2	[0–176]	B	NS	Naive	12000	584	11
	3	[160–336]	B	NS	Naive	20000	539	14
	4	[417–593]	B	NS	Naive	10000	416	16
	6	[789–965]	B	NS	Naive	1505	359	10
	8	[1070–1246]	B	NS	Naive	1900	367	11
SI1392	3	[0–134]	R-A/G	NS	Naive	1280	760	16
	5	[431–565]	R-A/G	NS	Naive	37000	232	8
	7	[739–873]	R-A/G	NS	Experienced	1148	357	12
	9	[1028–1162]	R-A/G	NS	Experienced	4300	227	11
	10	[1182–1316]	R-A/G	NS	Experienced	6100	245	8
CC2874	23	[1103–1263]	B	NS	Naive	11000	252	15
JG8930	28	[0–237]	B	NS	Naive	11000	908	14
JY3080	33	[0–183]	B	NS	Naive	NS	NS	10
JY3080	34	[182–365]	B	NS	Naive	101925	940	14
PR4290	30	[879–1089]	B	NS	Naive	1530	368	13
XE9655	23	[0–176]	B	NS	Naive	NS	NS	11
XE9655	28	[844–1020]	B	NS	Naive	36000	444	12
FQ2419	16	[756–2638]	B	IDU	Experienced	47000	327	19
FQ2419	18	[1134–3016]	B	IDU	Experienced	32000	301	11
DV6934	2	[0–245]	B	IDU	Naive	NS	377	15
NM1689	6	[0–173]	B	IDU	Naive	39000	836	10
	9	[594–767]	B	IDU	Experienced	53000	920	10
	10	[775–948]	B	IDU	Experienced	12000	646	10
	12	[1197–1370]	B	IDU	Experienced	1600000	658	10
SS0342	9	[0–177]	B	IDU	Naive	210000	352	15
	10	[160–337]	B	IDU	Naive	15000	487	12
	11	[354–531]	B	IDU	Experienced	3500	614	14
	13	[720–897]	B	IDU	Experienced	8800	325	12
	16	[1292–1469]	B	IDU	Experienced	8700	173	15
BQ7042	17	[1035–1267]	B	IDU	Experienced	9400	630	13
VE6375	25	[0–127]	B	IDU	Naive	16000	403	13
VE6375	27	[414–541]	B	IDU	Naive	140	260	15
EJ7211	14	[0–188]	B	Heterosexual	Naive	NI	909	12
	16	[358–546]	B	Heterosexual	Naive	2600	1220	11
	18	[699–887]	B	Heterosexual	Naive	140000	1449	9
	20	[1044–1232]	B	Heterosexual	Naive	33000	683	14
TI9054	3	[0–176]	B	NS	Naive	5800	795	18
	4	[166–342]	B	NS	Naive	19000	493	12
	5	[349–525]	B	NS	Naive	17453	427	12

The minimum duration of infection of each individual was the elapsed time between the date of first HIV positive documentation and the date of specimen collection. The maximum duration of infection was the time between the last HIV negative test and blood sample collection. NS, not stated ; Naive, subject has not received ART before this time point; Experienced, patient is currently or has previously received ART; IDU, intravenous drug user.

Back to article page

Table 1 WIHS specimens’ infection duration and viral and host factors.

Search

Quick links